Michael Thomas Heffernan Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Michael Thomas Heffernan.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Michael Thomas Heffernan. Michael Thomas Heffernan is Director in KERYX BIOPHARMACEUTICALS INC ($KERX) and Director in Ocata Therapeutics, Inc. ($ACTC) and Director in CORNERSTONE THERAPEUTICS INC ($CRTX) and Chairman, President and CEO in COLLEGIUM PHARMACEUTICAL, INC ($COLL) and Director in COLLEGIUM PHARMACEUTICAL, INC ($COLL) and in Akebia Therapeutics, Inc. ($AKBA) and Director in Akebia Therapeutics, Inc. ($AKBA) and Director in SYNLOGIC, INC. ($SYBX) and Director in Trevi Therapeutics, Inc. ($TRVI) and in Biohaven Pharmaceutical Holding Co Ltd. ($BHVN).
Latest Insider Trading Transactions of Michael Thomas Heffernan
| 1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
|---|---|---|---|---|---|---|---|
| No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, AKBA, BHVN, COLL, CRTX, KERX, ACTC, SYBX, TRVI
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 07 2021 | BHVN | Biohaven Pharmaceu ... | Heffernan Michael Thomas | Option Exercise | A | 71.94 | 11,996 | 862,992 | 11,996 | ||
| Mar 17 2021 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 25.88 | 3,031 | 78,442 | 4,047 | 7.1 K to 4 K (-42.82 %) |
| Mar 17 2021 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 25.26 | 47,044 | 1,188,331 | 7,078 | 54.1 K to 7.1 K (-86.92 %) |
| Dec 09 2020 | SYBX | SYNLOGIC, INC. | Heffernan Michael Thomas | Director | Option Exercise | A | 2.29 | 30,000 | 68,700 | 30,000 | |
| Jun 15 2020 | TRVI | Trevi Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | A | 4.10 | 14,210 | 58,261 | 14,210 | |
| Jun 09 2020 | AKBA | Akebia Therapeutic ... | Heffernan Michael Thomas | Option Exercise | A | 11.96 | 20,100 | 240,396 | 20,100 | ||
| Jun 09 2020 | AKBA | Akebia Therapeutic ... | Heffernan Michael Thomas | Grant | A | 0.00 | 13,700 | 0 | 34,886 | 21.2 K to 34.9 K (+64.67 %) | |
| May 15 2020 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 22.64 | 5,905 | 133,689 | 81,796 | 87.7 K to 81.8 K (-6.73 %) |
| May 15 2020 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 21.21 | 11,969 | 253,862 | 87,701 | 99.7 K to 87.7 K (-12.01 %) |
| May 15 2020 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 20.92 | 1,380 | 28,870 | 99,670 | 101.1 K to 99.7 K (-1.37 %) |
| May 01 2020 | BHVN | Biohaven Pharmaceu ... | Heffernan Michael Thomas | Option Exercise | A | 47.10 | 18,000 | 847,800 | 18,000 | ||
| May 01 2020 | BHVN | Biohaven Pharmaceu ... | Heffernan Michael Thomas | Option Exercise | A | 47.10 | 18,000 | 847,800 | 18,000 | ||
| Feb 12 2020 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Payment of Exercise | F | 21.62 | 4,962 | 107,278 | 101,050 | 106 K to 101.1 K (-4.68 %) |
| Jan 31 2020 | BHVN | Biohaven Pharmaceu ... | Heffernan Michael Thomas | Option Exercise | A | 48.49 | 36,000 | 1,745,640 | 36,000 | ||
| Jan 22 2020 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Option Exercise | M | 5.73 | 275,463 | 1,578,403 | 0 | |
| Jan 22 2020 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Payment of Exercise | F | 21.56 | 787 | 16,968 | 106,012 | 106.8 K to 106 K (-0.74 %) |
| Jan 22 2020 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 22.69 | 32,700 | 741,963 | 106,799 | 139.5 K to 106.8 K (-23.44 %) |
| Jan 22 2020 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 21.84 | 262,587 | 5,734,900 | 139,499 | 402.1 K to 139.5 K (-65.31 %) |
| Jan 22 2020 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Buy | M | 5.73 | 275,463 | 1,578,403 | 402,086 | 126.6 K to 402.1 K (+217.55 %) |
| Aug 13 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Payment of Exercise | F | 11.24 | 4,779 | 53,716 | 126,623 | 131.4 K to 126.6 K (-3.64 %) |
| Aug 13 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Payment of Exercise | F | 11.24 | 4,779 | 53,716 | 126,623 | 131.4 K to 126.6 K (-3.64 %) |
| Jul 23 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Payment of Exercise | F | 10.35 | 667 | 6,903 | 131,402 | 132.1 K to 131.4 K (-0.51 %) |
| Jul 17 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 11.26 | 25,000 | 281,500 | 132,069 | 157.1 K to 132.1 K (-15.92 %) |
| Jun 19 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 12.05 | 2,021 | 24,353 | 157,069 | 159.1 K to 157.1 K (-1.27 %) |
| Jun 19 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 11.31 | 22,979 | 259,892 | 159,090 | 182.1 K to 159.1 K (-12.62 %) |
| Jun 10 2019 | AKBA | Akebia Therapeutic ... | Heffernan Michael Thomas | Option Exercise | A | 4.23 | 20,100 | 85,023 | 20,100 | ||
| Jun 10 2019 | AKBA | Akebia Therapeutic ... | Heffernan Michael Thomas | Grant | A | 0.00 | 13,700 | 0 | 21,186 | 7.5 K to 21.2 K (+183.01 %) | |
| May 13 2019 | TRVI | Trevi Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | C | 0.00 | 34,247 | 0 | 0 | |
| May 13 2019 | TRVI | Trevi Therapeutics ... | Heffernan Michael Thomas | Director | Buy | P | 10.00 | 2,500 | 25,000 | 6,351 | 3.9 K to 6.4 K (+64.92 %) |
| May 13 2019 | TRVI | Trevi Therapeutics ... | Heffernan Michael Thomas | Director | Buy | C | 0.00 | 3,851 | 0 | 3,851 | 0 to 3.9 K |
| May 08 2019 | TRVI | Trevi Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | A | 10.00 | 23,684 | 236,840 | 23,684 | |
| Apr 30 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Option Exercise | A | 14.57 | 9,414 | 137,162 | 9,414 | |
| Apr 30 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Option Exercise | A | 14.57 | 9,414 | 137,162 | 9,414 | |
| Apr 30 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 4,707 | 0 | 207,069 | 202.4 K to 207.1 K (+2.33 %) |
| Apr 30 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 4,707 | 0 | 207,069 | 202.4 K to 207.1 K (+2.33 %) |
| Apr 17 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 15.87 | 4,808 | 76,303 | 202,362 | 207.2 K to 202.4 K (-2.32 %) |
| Apr 17 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 14.91 | 20,192 | 301,063 | 207,170 | 227.4 K to 207.2 K (-8.88 %) |
| Mar 19 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 17.17 | 25,000 | 429,250 | 227,362 | 252.4 K to 227.4 K (-9.91 %) |
| Feb 20 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 15.06 | 7,068 | 106,444 | 252,362 | 259.4 K to 252.4 K (-2.72 %) |
| Feb 20 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 14.71 | 17,932 | 263,780 | 259,430 | 277.4 K to 259.4 K (-6.47 %) |
| Feb 11 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Payment of Exercise | F | 14.39 | 7,851 | 112,976 | 277,362 | 285.2 K to 277.4 K (-2.75 %) |
| Jan 23 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Payment of Exercise | F | 15.76 | 787 | 12,403 | 285,213 | 286 K to 285.2 K (-0.28 %) |
| Jan 17 2019 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 15.56 | 25,000 | 389,000 | 286,000 | 311 K to 286 K (-8.04 %) |
| Dec 18 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 18.57 | 3,313 | 61,522 | 311,000 | 314.3 K to 311 K (-1.05 %) |
| Dec 18 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 18.12 | 21,687 | 392,968 | 314,313 | 336 K to 314.3 K (-6.45 %) |
| Dec 13 2018 | AKBA | Akebia Therapeutic ... | Heffernan Michael Thomas | Director | Option Exercise | A | 8.94 | 25,000 | 223,500 | 25,000 | |
| Dec 13 2018 | AKBA | Akebia Therapeutic ... | Heffernan Michael Thomas | Director | Option Exercise | A | 10.05 | 11,229 | 112,851 | 11,229 | |
| Dec 13 2018 | AKBA | Akebia Therapeutic ... | Heffernan Michael Thomas | Director | Option Exercise | A | 17.53 | 11,229 | 196,844 | 11,229 | |
| Dec 13 2018 | AKBA | Akebia Therapeutic ... | Heffernan Michael Thomas | Director | Option Exercise | A | 16.17 | 18,716 | 302,638 | 18,716 | |
| Dec 13 2018 | AKBA | Akebia Therapeutic ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 7,486 | 0 | 7,486 | 0 to 7.5 K |
| Dec 13 2018 | KERX | KERYX BIOPHARMACEU ... | Heffernan Michael Thomas | Director | Option Exercise | D | 0.00 | 110,000 | 0 | 0 | |
| Dec 13 2018 | KERX | KERYX BIOPHARMACEU ... | Heffernan Michael Thomas | Director | Sell | D | 0.00 | 20,000 | 0 | 0 | 20 K to 0 (-100.00 %) |
| Nov 16 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 17.05 | 3,600 | 61,380 | 336,000 | 339.6 K to 336 K (-1.06 %) |
| Nov 16 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 16.53 | 21,400 | 353,742 | 339,600 | 361 K to 339.6 K (-5.93 %) |
| Oct 17 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Sell | S | 16.53 | 25,000 | 413,250 | 361,000 | 386 K to 361 K (-6.48 %) |
| Aug 27 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Payment of Exercise | F | 18.03 | 2,025 | 36,511 | 386,000 | 388 K to 386 K (-0.52 %) |
| Aug 06 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Director | Payment of Exercise | F | 20.15 | 668 | 13,460 | 388,025 | 388.7 K to 388 K (-0.17 %) |
| Jul 12 2018 | KERX | KERYX BIOPHARMACEU ... | Heffernan Michael Thomas | Director | Option Exercise | A | 3.76 | 30,000 | 112,800 | 30,000 | |
| Jul 12 2018 | KERX | KERYX BIOPHARMACEU ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 10,000 | 0 | 20,000 | 10 K to 20 K (+100.00 %) |
| Jun 13 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Sell | S | 25.26 | 53,057 | 1,340,220 | 388,693 | 441.8 K to 388.7 K (-12.01 %) |
| Jun 13 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Sell | S | 25.28 | 96,943 | 2,450,719 | 441,750 | 538.7 K to 441.8 K (-18.00 %) |
| Apr 23 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Sell | S | 26.01 | 100 | 2,601 | 545,793 | 545.9 K to 545.8 K (-0.02 %) |
| Apr 23 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Sell | S | 26.00 | 44,300 | 1,151,800 | 545,893 | 590.2 K to 545.9 K (-7.51 %) |
| Mar 01 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Payment of Exercise | F | 21.77 | 4,050 | 88,169 | 590,193 | 594.2 K to 590.2 K (-0.68 %) |
| Feb 06 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Payment of Exercise | F | 23.38 | 788 | 18,423 | 594,243 | 595 K to 594.2 K (-0.13 %) |
| Jan 29 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Option Exercise | A | 24.35 | 150,000 | 3,652,500 | 150,000 | |
| Jan 29 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Grant | A | 10.17 | 1,044 | 10,617 | 595,031 | 594 K to 595 K (+0.18 %) |
| Jan 29 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Grant | A | 0.00 | 75,000 | 0 | 593,987 | 519 K to 594 K (+14.45 %) |
| Jan 23 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Sell | S | 25.01 | 16,408 | 410,364 | 518,987 | 535.4 K to 519 K (-3.06 %) |
| Jan 23 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Sell | S | 25.00 | 3,592 | 89,800 | 535,395 | 539 K to 535.4 K (-0.67 %) |
| Jan 19 2018 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Sell | S | 22.50 | 20,000 | 450,000 | 538,987 | 559 K to 539 K (-3.58 %) |
| Nov 17 2017 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Sell | S | 15.53 | 50,000 | 776,500 | 558,987 | 609 K to 559 K (-8.21 %) |
| Aug 04 2017 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Payment of Exercise | F | 12.39 | 736 | 9,119 | 608,987 | 609.7 K to 609 K (-0.12 %) |
| Aug 04 2017 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Grant | A | 10.60 | 640 | 6,784 | 609,723 | 609.1 K to 609.7 K (+0.11 %) |
| Jun 20 2017 | KERX | KERYX BIOPHARMACEU ... | Heffernan Michael Thomas | Director | Option Exercise | A | 6.56 | 30,000 | 196,800 | 30,000 | |
| Jun 20 2017 | KERX | KERYX BIOPHARMACEU ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 10,000 | 0 | 10,000 | 0 to 10 K |
| Mar 21 2017 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Payment of Exercise | F | 14.95 | 1,472 | 22,006 | 609,083 | 610.6 K to 609.1 K (-0.24 %) |
| Feb 02 2017 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Option Exercise | M | 0.48 | 3,013 | 1,446 | 0 | |
| Feb 02 2017 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Buy | M | 0.48 | 3,013 | 1,446 | 555,555 | 552.5 K to 555.6 K (+0.55 %) |
| Feb 02 2017 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Grant | A | 10.08 | 1,239 | 12,489 | 552,542 | 551.3 K to 552.5 K (+0.22 %) |
| Aug 03 2016 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Grant | A | 10.31 | 1,212 | 12,496 | 551,303 | 550.1 K to 551.3 K (+0.22 %) |
| Jun 23 2016 | KERX | KERYX BIOPHARMACEU ... | Heffernan Michael Thomas | Director | Option Exercise | A | 6.05 | 50,000 | 302,500 | 50,000 | |
| Apr 07 2016 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Option Exercise | M | 0.48 | 3,931 | 1,887 | 3,013 | |
| Apr 07 2016 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Option Exercise | M | 3.31 | 9,673 | 32,018 | 0 | |
| Apr 07 2016 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Buy | M | 0.48 | 3,931 | 1,887 | 387,048 | 383.1 K to 387 K (+1.03 %) |
| Apr 07 2016 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Buy | M | 3.31 | 9,673 | 32,018 | 383,117 | 373.4 K to 383.1 K (+2.59 %) |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | D | 8.36 | 5,000 | 41,800 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | D | 6.39 | 10,000 | 63,900 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | D | 7.94 | 100,000 | 794,000 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | D | 6.17 | 10,000 | 61,700 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | D | 6.00 | 1,250 | 7,500 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | D | 5.79 | 5,000 | 28,950 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | D | 8.00 | 3,621 | 28,968 | 0 | |
| Feb 11 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Sell | U | 8.50 | 31,000 | 263,500 | 0 | 31 K to 0 (-100.00 %) |
| Jan 22 2016 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Option Exercise | A | 16.15 | 109,005 | 1,760,431 | 109,005 | |
| Jan 22 2016 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Grant | A | 0.00 | 18,135 | 0 | 373,444 | 355.3 K to 373.4 K (+5.10 %) |
| Jan 04 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Option Exercise | A | 8.36 | 10,000 | 83,600 | 10,000 | |
| Jan 04 2016 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 2,500 | 0 | 31,000 | 28.5 K to 31 K (+8.77 %) |
| Oct 01 2015 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 2,500 | 0 | 28,500 | 26 K to 28.5 K (+9.62 %) |
| Jul 02 2015 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 2,500 | 0 | 26,000 | 23.5 K to 26 K (+10.64 %) |
| May 18 2015 | COLL | COLLEGIUM PHARMACE ... | Heffernan Michael Thomas | Chairman, President ... | Option Exercise | A | 14.90 | 70,193 | 1,045,876 | 70,193 | |
| Apr 01 2015 | ACTC | Ocata Therapeutics ... | Heffernan Michael Thomas | Director | Grant | A | 0.00 | 2,500 | 0 | 23,500 | 21 K to 23.5 K (+11.90 %) |
| Feb 04 2014 | CRTX | CORNERSTONE THERAP ... | Heffernan Michael Thomas | Director | Option Exercise | D | 8.34 | 15,000 | 125,100 | 0 | |
| Feb 04 2014 | CRTX | CORNERSTONE THERAP ... | Heffernan Michael Thomas | Director | Option Exercise | D | 5.11 | 15,000 | 76,650 | 0 | |
| Feb 04 2014 | CRTX | CORNERSTONE THERAP ... | Heffernan Michael Thomas | Director | Option Exercise | D | 7.15 | 15,000 | 107,250 | 0 | |
| Feb 04 2014 | CRTX | CORNERSTONE THERAP ... | Heffernan Michael Thomas | Director | Option Exercise | D | 5.97 | 10,000 | 59,700 | 0 | |
| Feb 04 2014 | CRTX | CORNERSTONE THERAP ... | Heffernan Michael Thomas | Director | Option Exercise | D | 7.09 | 5,833 | 41,356 | 0 | |
| Feb 04 2014 | CRTX | CORNERSTONE THERAP ... | Heffernan Michael Thomas | Director | Option Exercise | D | 2.93 | 15,000 | 43,950 | 0 | |
| Feb 04 2014 | CRTX | CORNERSTONE THERAP ... | Heffernan Michael Thomas | Director | Option Exercise | D | 3.90 | 3,571 | 13,927 | 0 | |
| May 23 2013 | CRTX | CORNERSTONE THERAP ... | Heffernan Michael Thomas | Director | Option Exercise | A | 8.34 | 15,000 | 125,100 | 15,000 | |
| May 23 2012 | CRTX | CORNERSTONE THERAP ... | Heffernan Michael Thomas | Director | Option Exercise | A | 5.11 | 15,000 | 76,650 | 15,000 | |
| May 19 2011 | CRTX | CORNERSTONE THERAP ... | Heffernan Michael Thomas | Director | Option Exercise | A | 7.15 | 15,000 | 107,250 | 15,000 | |
| May 24 2010 | CRTX | CORNERSTONE THERAP ... | Heffernan Michael Thomas | Director | Option Exercise | A | 5.97 | 10,000 | 59,700 | 10,000 | |
| Jun 01 2009 | CRTX | CORNERSTONE THERAP ... | Heffernan Michael Thomas | Director | Option Exercise | A | 7.09 | 5,833 | 41,356 | 5,833 | |
| Dec 18 2008 | CRTX | CORNERSTONE THERAP ... | Heffernan Michael Thomas | Director | Option Exercise | A | 2.93 | 15,000 | 43,950 | 15,000 |
Page: 1